

Tegretol<sup>®</sup> controls seizures without  
sedation *and* improves behaviour and mood

Geigy



Tegretol is available as  
white-scored  
compressed tablets  
containing 200 mg  
5-Carbamoyl-5H-dibenz  
(b,f) azepine  
(Carbamazepine)

Detailed literature  
describing any Geigy  
product will be supplied  
on request.  
Geigy Pharmaceuticals,  
Macclesfield, Cheshire.



## There's nothing quite like Penbritin

Penbritin (ampicillin) offers broad-spectrum, bactericidal activity against the bacteria commonly causing infections in children. It has the potent activity of penicillins against common Gram-positive organisms, but in addition allows effective oral treatment of infections caused by Gram-negative species—such as *Haemophilus influenzae* and *E. coli*.

Increasing attention has to be paid to problems of toxicity: 'Because of serious effects on tooth development, tetracyclines are absolutely contra-indicated for children aged under 8...' Penbritin, in contrast, retains the acknowledged

safety of the penicillins.

Penbritin is well accepted by children—there are two strengths of palatable syrup, capsules, tablets, injectables and now the new paediatric suspension.

Finally, Penbritin is well-proven. In published references involving more than 1,000 children, Penbritin's success rates were 91% in Respiratory Infections, 84% in Otitis Media, 88% in Urinary Tract Infections and 87% in severe infections such as Meningitis.

Reference: 1. Brit. med. J., (1970), 4,509

*Further information is available on request*

## Penbritin—first line treatment for infections in children



Penbritin\* (ampicillin) is a British product originated by  
**Beecham Research Laboratories, Brentford, England.**

\*regd.



# Mead Johnson products

## for choice in the dietary treatment of

### **MILK INTOLERANCE**

#### **NUTRAMIGEN**

Complete hydrolysed protein  
formula.

#### **SOBEE\***

Complete lactose free  
soya formula.

#### **PROSOBEE\***

Complete lactose free  
liquid formula.

### **FAT INTOLERANCE**

#### **PORTAGEN\***

Complete medium chain  
triglyceride formula.

#### **MCT\*** Oil

Medium chain  
triglyceride oil.

### **PHENYLKETONURIA**

#### **LOFENALAC**

Complete low  
phenylalanine formula.

All of these products may be prescribed on form  
E.C.10 for the treatment of specific conditions.

\*Recipe booklets available on request.

Full information on all products available from

# Mead Johnson

Mead Johnson Laboratories Division of Bristol-Myers Company Ltd.,  
Stamford House, Langley, Bucks.

# In epilepsy First steps towards a stable future

'Mysoline' therapy is accepted by even the youngest epileptic patient. The pleasantly flavoured suspension controls most types of attacks or sharply reduces their frequency and severity, without clouding of consciousness or dulling of intellect.

Improvement in general behaviour and sociability usually occurs and education remains unimpeded.

**Mysoline** PRIMIDONE B.P. TRADE MARK  
suspension

of fundamental importance in epilepsy.



THE QUEEN'S  
AWARD  
TO INDUSTRY  
1966 1967 1968  
1969 1970

*Free starter pack and detailed  
information are available on request.*

Imperial Chemical Industries Limited,  
Pharmaceuticals Division,  
Alderley House, Alderley Park, Macclesfield, Cheshire.

PH 712



**A new  
palatable presentation  
of pancreatin granules.**

**ZYPANAR**

**considerably reduces  
the taste associated  
with normal pancreatins.**

Zypanar granules contain proteolytic and amylolytic activities equivalent to Pancreatin 3.N.F. It also contains lipolytic activity equivalent to not less than 20 lipase u./gm. (Willstater). The granules are wax-protected so that optimum effect occurs in the intestines. It has been found that the presentation considerably reduces the taste associated with normal Pancreatin.

**Indicated in**  
Cystic Fibrosis  
Steatorrhea  
Pancreatitis  
Other symptoms of Pancreatic  
Deficiency

**Packs**  
Bottles of 200 and 500  
grammes.

Full information is available on request:  
**Armour Pharmaceutical Company Limited**  
Eastbourne, Sussex, England.




JA2 ZY 2

# "A safe and effective method of treating house dust mite sensitivity"<sup>1</sup>

This was the conclusion reached by a group of British clinicians, in a preliminary report on ALLPYRAL-MITE FORTIFIED HOUSE DUST.

For those patients with house dust mite sensitivity, ALLPYRAL-MITE FORTIFIED HOUSE DUST offers specific hypo-sensitisation therapy; the preliminary report, on an uncontrolled trial, suggests that good results might be achieved in as many as 83% of patients.



1. (1970)—IN PRESS.

## Allpyral mite fortified house dust

Like all Allpyral allergen extracts, mite fortified house dust is prepared by pyridine extraction and alum precipitation. This type of extract has been shown to give fewer reactions than the traditional aqueous extracts.

Full information is available on request




**DOME**

LABORATORIES, DIVISION OF MILES LABORATORIES LTD  
STOKE COURT, STOKE POSES, SLOUGH, BUCKS. TEL: FARNHAM COMMON 2151



ALLPYRAL is a trade mark DM 444

# FAT CHILDREN



Obesity in childhood is becoming recognised as a very common problem. In fact it is the commonest nutritional disorder of childhood in developed countries.

It has been shown that rates of atherosclerotic heart disease, hypertensive heart disease, cardiovascular renal disease and diabetes mellitus are higher amongst those who were overweight in childhood.

Children become obese because their calorie intake exceeds their particular requirements and is quite commonly developed in early infancy.

The dietary control of established obesity in childhood is notoriously difficult and here many factors are playing a part. In these circumstances the combination of dietary control and drug treatment can often be more successful.

Amphetamine-like compounds, with their risks of central stimulation, addiction and tolerance, are better avoided.

Ponderax (fenfluramine) which is without these effects can be used very beneficially in established obesity in children.\*

\* (1971) South African Medical Journal 45. Suppl. 40.

the role of **PONDERAX**<sup>®</sup>  
FENFLURAMINE



Full information available from:

**Servier Laboratories Limited**

Percival House, Pinner Road, Harrow, Middlesex. HA1 4HQ

S554-7

# PKU treatment simple · effective · safe · low cost

## ALBUMAID XP

Albumaid XP has an unequalled record in the active growing period in a child's life in respect of height, weight and neurological development. It contains all the essential elements of beef and is just as palatable. Every child is safe with Albumaid XP.

## PKAID I

PKAID I allows a variation in the low-phenylalanine diet of children who are 3 years old and upwards and this is of great value. Other alternatives cost considerably more. You can reduce your prescribing costs with PKAID I.

## PKAID II

PKAID II is excellent for older children on a low protein high calory diet. They will benefit considerably from its inclusion in your treatment with as little as 10 grams a day. Your prescribing costs will be greatly reduced with PKAID II.

## REFERENCE

Phenylketonuria. A monograph edited by  
H. Bickel, F. P. Hudson and L. I. Woolf.  
Published by Georg Thieme Verlag, Stuttgart.

---

**Issued by MILNER SCIENTIFIC AND MEDICAL RESEARCH**

(An Organization which links Advanced Researches in Europe and United States)

*For further details please write to sole U.K. Agents:*

**SCIENTIFIC HOSPITAL SUPPLIES LTD.  
38 QUEENSLAND STREET, LIVERPOOL 7**



# TRIALS CONFIRM FLOXAPEN'S EXCELLENT PERFORMANCE

Treatment succeeded clinically in 26 patients with staphylococcal infections and failed in four. It was unsuccessful either clinically or bacteriologically in two of three patients with pneumococcal infections. There were no serious side-effects. No undue pain was experienced at the site of the injection. It is concluded that flucloxacillin is a useful addition to the therapeutic armamentarium against benzylpenicillin-resistant staphylococci.

Flucloxacillin has made any dramatic cures of staphylococcal infection with new agents less impressive and remarkable than would have been the case with other penicillins. Highly satisfactory responses were obtained with flucloxacillin at a dosage of 1.0 g daily, and cures obtained late in the trial in very ill patients using higher dose regimes can only be assessed as excellent by comparison with any other currently-available compounds. It became apparent as the trial continued that severe staphylococcal infection contained by the

Above: Clinical Trials J. (1970) 7, 375.

Right: Clinical Trials J. (1970) 7, 372.

Floxapen, like Orbenin (cloxacillin B.P.), is active against virtually all staphylococci and all streptococci and pneumococci irrespective of their sensitivity to traditional penicillins, tetracyclines, fusidic acid, erythromycin and lincomycin.

The standard dose of Floxapen is only 250 mg. and will attain similar serum levels by oral or injectable routes. Therapy is therefore simpler and more effective than with Orbenin.

Floxapen offers the penicillin advantages of low toxicity and bactericidal action. It is also ideal for continuing outpatient treatment because of its convenient oral dosage.

Further information is available on request.

**Indications:** Infections due to sensitive Gram-positive organisms, including resistant staphylococci: skin and soft tissue infections, otitis media, sinusitis, infected wounds and burns, osteomyelitis and septic arthritis, pneumonia empyema, septicaemia, endocarditis and meningitis.

**Dosage** Oral and intramuscular:  
Adults: 250 mg. q.i.d.  
Children: 2-10 years— $\frac{1}{2}$  adult dose.  
Under 2 years— $\frac{1}{4}$  adult dose.

Oral doses should be taken one hour before meals. In severe infections dosages may be increased if required.

**Availability** Syrup 125 mg./5 ml.  
Capsules (black/caramel) and  
Vials, each containing 250 mg. flucloxacillin.

**Contra-indications** Penicillin hypersensitivity.  
Subconjunctival injection.

**Side-effects** As with other penicillins.


**Floxapen** simplifies antibiotic treatment  
in hospital and after  
*flucloxacillin*



Floxapen\* (flucloxacillin) is a British product originated by

**Beecham Research Laboratories, Brentford, England.** \*regd






## Aminogran improves the dietary management of phenylketonuria

In the dietary management of phenylketonuria, protein hydrolysate based foods tend to be unpalatable and difficult to administer. Compared with them, Aminogran is less unpalatable, smaller in bulk, and can be given as a medicine. It does not, therefore, interfere greatly with the child's appetite for permitted foods, and the diet can more closely resemble that of a normal child.

An Aminogran based diet is more readily accepted by the child and creates fewer family problems. Anorexia, food fussiness and emotional disturbances are much reduced.

"The children accepted it (Aminogran) easily and fed it to themselves instead of having to be spooned or force fed, and consequently the quality of family life improved."

*Arch. Dis. Childh.* (1970) 45, 640.



Each carton of Aminogran includes a 150g container of amino acid food supplement and a 50g container of mineral mixture.

Full information is available on request.  
Aminogran is a Trade Mark of

ALLEN & HANBURY LTD LONDON E2 6LA



# Admit an emergency. Admit a case for Ceforin.

A child has been admitted.  
She's been vomiting, is now comatose and  
has neck rigidity.  
She also has an ear infection which hasn't  
responded to penicillin treatment.  
It all points to meningitis.  
And a penicillin-resistant organism.  
You'll admit there's a case for Ceforin.

Ceforin kills the majority of gram-positive  
and gram-negative organisms.  
It also kills the penicillin-resistant staph.  
And it's as painless as an injection can be.

When you suspect meningitis, you can  
trust Ceforin to act fast.  
Give it intravenously. Give it intrathecally too.  
So you can ensure adequate CSF levels.  
And eradicate the infection.

With meningitis you're dealing with  
an emergency. And you'll admit that's  
the case for Ceforin.

## Ceforin

**Glaxo** 

For detailed information on  
Ceforin (trade mark) write to  
Glaxo Laboratories Ltd  
Greenford, Middlesex

Presentation  
Vials containing 100mg, 250mg, 500mg  
and 1 gram cephalexin in boxes of five

“...not only are the two primary pathogens, *Strep pneumoniae* and *H influenzae*, sensitive, but so are the secondary invaders such as *klebsiella* which often replace them after antibiotic treatment.”<sup>1</sup>

“...clearly superior to either of the other treatments...”<sup>2</sup>

“...indeed one cannot remember any other drug performing so well...”<sup>3</sup>

“...one is struck by the tremendous success rate, certainly superior to any antibacterial we have tested...”<sup>3</sup>

“It rapidly cleared purulent sputum with improvement in all 50 cases.”<sup>4</sup>

“Of the easily administered primary treatments for urinary tract infection, this combination is probably the best.”<sup>1</sup>

SEPTRIN® Tablets, Adult Suspension, Paediatric Suspension and Paediatric Tablets contain trimethoprim and sulphamethoxazole.


References to the role of the trimethoprim: sulphonamide combination in treating bronchitis and urinary infections

(1) *S Afr med J*, (1970) **44**, Supplement (August) 12.

(2) Leading Article, *Brit med J*, (1969) **1**, 525.

(3) *Med J Austr* (1971), **1**, 526.

(4) Proceedings of the V International Congress of Chemotherapy, (1967), **1**, **1**, (A1 - 5a/3) 293.



# SEPTRIN

eradicates infection by a  
double blockade of bacterial metabolism



\*Trade Mark

Wellcome Burroughs Wellcome & Co. (The Wellcome Foundation Ltd.) Dartford, Kent, DA1 5AH.

Full information is available on request.



# ONLY COTAZYM

## has accurately assayed lipase activity

Pancreatic replacement therapy  
can be adjusted to cover the exact amount  
of fat in the patient's diet

**Cotazym** is the only pancreatic extract with known, measurable and constant lipase activity, in addition to adequate measured amounts of trypsin and amylase. It allows simple but accurate estimation of dosage ensuring greater control over dietary intake.

**Each capsule contains:**

lipase sufficient to digest 17g dietary fat  
trypsin sufficient to digest 34g dietary protein  
amylase sufficient to digest 40g dietary starch.

**Indications:**

pancreatic deficiency states including post-gastrectomy malabsorption, fibrocystic disease and gastro-intestinal disorders resulting in steatorrhoea.

**Dosage:**

dosage is calculated on the fat digesting power of the lipase. 2 to 3 capsules taken with each main meal and one capsule with a snack is sufficient to cover normal daily fat intake. The contents of the capsule should be sprinkled over the food.



Organon Laboratories Ltd · Crown House · Morden · Surrey

*New clinical and experimental studies for pediatricians, clinicians, and surgeons . . .*

## PROGRESS IN PEDIATRIC SURGERY, Volume 3

Edited by P. P. Rickham, W. Ch. Hecker, and J. Prévot

This newest volume in the *Progress in Pediatric Surgery* series presents ten detailed, authoritative articles on subjects of specific, topical importance to pediatric surgeons and pediatricians. In addition to considerations of intensive therapy and care for the newborn, this volume presents contributions on funnel chest and other congenital chest deformities, intestinal obstruction, congenital disturbances of the urinary tract, portal vein abnormalities, and functional problems of the cardia. Three articles of particular interest to anesthesiologists as well as pediatric surgeons cover indications for and results of intermittent positive pressure breathing, and ventilator design, followed by a section of provocative discussions on controversial aspects of artificial ventilation and ethical considerations in clinical policy.

### CONTENTS

#### Volume 3:

**The Forms of Congenital Deformities of the Chest and their Treatment** M. M. Ravitch

**The Etiology and Pathogenesis of Funnel Chest.** H. Geisbe, H. Mildenberger, A. Flach, and H. Fendel

**Functional Obstruction of the Intestine due to Neurological Immaturity.** A. G. Bughagis and J. L. Emery

**Effects of Subvesical Disturbances of Urinary Drainage on the Upper Urinary Tract in Childhood.** H. Mildenberger and H. Fendel

**Administration and Design for Intensive Therapy in Surgery of the Newborn.** J. F. R. Bentley

**The Indications for Intermittent Positive Pressure Breathing.** G. Jackson Rees

**The Features and Design of Ventilators.** J. S. Inkster

**The Results of Long-Term Positive Pressure Ventilation in Newborn Surgical Patients.** E. F. Battersby

**Intensive Care and Therapy of the Newborn.** Selected discussions from the 17th International Congress of the British Association of Pediatric Surgeons

**Predoduodenal Portal Vein.** P. Braun and A. Cuendet

**The Function of Cardia in Childhood.** E. Willich

173 pages Illus. January 1972 \$13.50

#### Volume 1:

**The "E.M.G." Syndrome (Exomphalos, Macroglossia, Gigantism).** Irving

**Infantile Pyloric Stenosis (Historical Aspects and Current Surgical Concepts).** Benson

**The Small Kidney.** Ericsson

**The Use of Synthetic Polymeric Materials as Suture Substitutes and Their Place in Pediatric Surgery.** Heiss

**Portal Hypertension in Childhood.** Prévot, et al.

**Spontaneous Perforations of the Biliary Tract in Infancy.** Prévot and Babut

**Postoperative Complications following Operation for Esophageal Atresia and Tracheo-esophageal Fistula.** Daum

237 pages Illus. 1970 \$12.50

#### Volume 2 (Neonatal Surgery):

**Past, Present, and Future of Neonatal Surgery and Neonatal Surgical Units.** Rickham

**Recent Advances in Postoperative Management of Newborn Infants.** Koop

**Recent Advances in the Surgery of the Diaphragm in the Newborn.** Lister

**Recent Advances in the Surgery of Esophageal Atresia.** Koop

**Intestinal Obstruction.** Zachary

**Intraluminal Intestinal Obstruction.** Rickham

**Recent Advances in the Management of Anorectal Abnormalities.** Johnston

**Recent Advances in the Management of Low Urinary Obstruction in the Newborn.** Hendren

**Exstrophy of the Bladder.** Johnston

**Recent Advances in the Management of Myelomeningoceles.** Zachary

**Recent Advances in the Use of Prosthetics in Neonatal Surgery.** Lister

186 pages Illus. 1971 \$13.50

Volume 4 of *Progress in Pediatric Surgery* will be published in May 1972. Future volumes will be published at the rate of about two per year. Your continuation order for the series ensures automatic shipment of each new volume immediately upon publication.

### LANGUAGE OF THE MENTALLY RETARDED

Edited by Richard L. Schiefelbusch

A detailed, authoritative study by leading clinicians and experimentalists in speech pathology, linguistics, mental retardation, neurology, and the behavioral sciences. Specifically designed as a comprehensive reference on the linguistic problem, presenting thirteen important original contributions ranging from language development and defective speech delineation to experimental procedures for promoting language acquisition in the retarded. In addition to extensive presentations of newly-developed linguistic theory and data, this volume contains a wealth of previously unpublished material on developmental aspects of language acquisition, interpersonal variables affecting relationships between speakers and listeners, reciprocal factors influencing communication events, and physiological features in studies of defective language.

250 pages Illus. February 1972 \$12.50

### LANGUAGE INTERVENTION WITH THE RETARDED

Edited by James E. McLean, David E. Yoder, and Richard L. Schiefelbusch

A systematic, analytic approach to intervention programming for speech and language development among the retarded, using the tools of psycholinguistic tenets and operant conditioning approaches to instructional problems. The process of language acquisition by normal children is analyzed, methods for identifying the nature and extent of disorders of speech and language are suggested, and programs for clinical treatment are presented. Provides a wide range of complementary theoretical and clinical notations and guidelines for practical application in language-development programming.

260 pages Illus. April 1972 \$11.50

Overseas customers should order through their usual bookseller. In Europe and the U.K. all University Park Press books are stocked for immediate shipment at European Bookservice, Weesp, Netherlands.

**UNIVERSITY PARK PRESS**

Chamber of Commerce Building  
Baltimore, Maryland 21202



INTERNATIONAL PUBLISHERS  
IN SCIENCE AND MEDICINE


# PRACTICAL TEXTS IN PAEDIATRICS

## 17 Books Selected from the Thomas Catalog of over 2325 Titles . . .

- **THE BIOCHEMICAL AND IMMUNOLOGICAL BASIS OF BRONCHIAL ASTHMA** by Kjell Aas, *Univ. of Oslo, Norway.* '72, 256 pp., 37 ill., \$11.50.
- **PATTERNS OF SKIN pH FROM BIRTH THROUGH ADOLESCENCE: With a Synopsis on Skin Growth** by Hans Behrendt and Marvin Green, *both of New York Medical College, New York City.* '71, 116 pp. (6½ × 9½), 33 ill., 41 tables, \$8.25.
- **AN ATLAS OF THE OSTEOCHONDROSES** by Louis W. Breck, *The El Paso Orthopaedic Surgery Group. Foreword by Charles Weer Goff.* '71, 192 pp. (6½ × 9½), 53 ill., 8 tables, \$12.50.
- **PREVENTION OF Rh-HEMOLYTIC DISEASE** by Cyril A. Clarke and Richard B. McConnell, *both of The Univ. of Liverpool, England.* '72, 136 pp., 13 ill., 29 tables, \$15.50.
- **A MANUAL OF RESPIRATORY FAILURE: Tracheostomy, Endotracheal Intubation and Mechanical Ventilation** by Eli Rush Crews and Leopoldo Lapuerta, *both of Univ. of Texas Medical School, San Antonio. Foreword by Sydney Schiffer.* '72, 212 pp., 43 ill., 19 tables, \$11.75.
- **RADIOGRAPHY OF INFANTS AND CHILDREN [2nd Ed.]** by Donald B. Darling, *Tufts Univ. School of Medicine. Foreword by John Caffey. (4 Contributors.)* '71, 236 pp. (9 × 12), 591 ill., 81 tables, \$28.50.
- **AN INTRODUCTION TO DIABETES FOR THE YOUNG CHILD** written and illustrated by Mary Pinckney Ferguson, *Washington Diabetes Association, Seattle. Foreword by Robert H. Williams.* '72, 48 pp. (5½ × 8½), 24 ill. Minimum order in groups of 5 copies, \$7.50.
- **ADOLESCENT SUICIDE** by Stuart M. Finch, and Elva O. Poznanski, *both of Univ. of Michigan Medical School, Ann Arbor. Foreword by Raymond W. Waggoner.* '71, 84 pp., 4 tables, \$6.75.
- **SURGERY AND THE ALLERGIC PATIENT** edited by Charles A. Frazier, *Asheville, North Carolina. Foreword by Warren H. Cole and L. Nelson Bell. (12 Contributors.)* '71, 212 pp. (6½ × 9½), 44 ill. (7 in full colour), 8 tables, \$12.50.
- **ORTHOPAEDIC SURGERY IN SPASTICITY. Orthopaedic Lectures: Volume I** by Harold M. Frost, *Henry Ford Hospital, Detroit.* '72, 228 pp., 51 ill., 43 tables, \$13.00.
- **THE NATURAL HISTORY AND PROGRESS IN TREATMENT OF CONGENITAL HEART DEFECTS: An International Symposium** Sponsored by the Ontario Heart Foundation in Cooperation with The Hospital for Sick Children and the University of Toronto edited by B. S. Langford Kidd and John D. Keith, *both of Univ. of Toronto, Ontario, Canada. (35 Contributors.)* '71, 360 pp. (7 × 10), 163 ill., 71 tables, \$19.75.
- **COMPREHENSIVE MANAGEMENT OF EPILEPSY IN INFANCY, CHILDHOOD AND ADOLESCENCE** by Samuel Livingston, *The Johns Hopkins Univ. School of Medicine, Baltimore. Assisted by Irving M. Pruce. Contributions by Dietrich Blumer, Samuel Karelitz and A. Earl Walker.* '72, 672 pp., (6½ × 9½), 62 ill. (14 in full colour), 33 tables, \$27.50.
- **THE PATHOPHYSIOLOGY AND TREATMENT OF DROWNING AND NEAR-DROWNING** by Jerome H. Modell, *Univ. of Florida College of Medicine, Gainesville. Foreword by Frank Moya.* '71, 136 pp., 19 ill., 13 tables, \$9.50.
- **DRUGS, DEVELOPMENT, AND CEREBRAL FUNCTION** compiled and edited by W. Lynn Smith, *Porter Memorial Hospital, Denver and White Memorial Medical Center, Los Angeles. Foreword by Marcel Kinsbourne. (25 Contributors.)* '72, 424 pp. (6½ × 9½), 80 ill., 43 tables, \$22.00.
- **JUVENILE-TYPE DIABETES AND ITS COMPLICATIONS: Theoretical and Practical Considerations** by Karl E. Sussman, *Univ. of Colorado Medical School, Denver. Foreword by Alexander Marble. (14 Contributors.)* '71, 506 pp. (6½ × 9½), 123 ill. (6 in full colour), 39 tables, \$32.50.
- **ASTHMA AND HAY FEVER** by Oscar Swineford, Jr., *President, American Association of Certified Allergists.* '71, 508 pp., 1 ill., 72 tables, \$19.50.
- **OSTEOMYELITIS: Clinical Features, Therapeutic Considerations, and Unusual Aspects** by Francis A. Waldvogel, *Univ. of Geneva Medical School, Switzerland; Gerald Medoff, Washington Univ. School of Medicine, St. Louis; and Morton N. Swartz, Massachusetts General Hospital, Boston.* '71, 128 pp., 27 ill., 11 tables, \$8.25.

# Metabolic Aspects of Disease

Treatment of inborn errors has advanced our basic knowledge of disease. Metabolic problems are also a frequent consequence of disease.



Day-time variations in serum phenylalanine (triangles) and tyrosine (circles) in a phenylketonuric child having his first meal as usual at 07.45 hrs or fasting until 11.45 hrs. Note the phenylalanine depressing effect of the breakfast (phenylalanine-restricted meal with Albumaid (R) (Güttler, Olesen & Wamberg—Kennedy Institute—Denmark in *Enzymopenic Anaemias, Lysosomes and other papers*, pages 149-158 E. & S. Livingstone.)

## PRECISION PRODUCTS:

Designed to meet the metabolic defect are called for.

Products more fundamental than enzymes.

Products more basic than protein.

Products which enable precise nutrition.

Products which succeed where cows' milk is a failure.

## PRECISION PRODUCTS FOR:

Phenylketonuria, Homocystinuria, Cystinosis, Maple Syrup Urine Disease, Hyperglycinaemia, Hyperprolinaemia, Arginine Succinic Urea, Histidinaemia, Tyrosinosis, Carbohydrate and Protein Intolerance, Malabsorptions, Cystic Fibrosis, Glycogen Storage Disease.

## MILNER SCIENTIFIC AND MEDICAL RESEARCH

Now maintains a world-wide interest in every aspect of metabolism in disease, and products are directly available in most countries.

For further details please write to Sole U.K. Agents:

SCIENTIFIC HOSPITAL SUPPLIES LTD.  
38 QUEENSLAND STREET, LIVERPOOL 7